Michael R. Bishop

High Impact

Professor of Medicine

UAMS

Also affiliated: University of Nebraska at Omaha (1997); Universitat Autònoma de Barcelona (2021); National Institutes of Health (2001–2012); University of Minnesota (2002); Nebraska Medical Center (1994–2000); Institute on Taxation and Economic Policy (2008); National Marrow Donor Program (2002–2005); University College London Hospitals NHS Foundation Trust (2024); The University of Texas MD Anderson Cancer Center (2008–2009); Cancer Research Institute (2005); Loyola University Chicago (1991); University of Washington (2002); Peking University (2013); Medical College of Wisconsin (1998–2012); University Hospitals Bristol NHS Foundation Trust (2024); Cancer Institute (WIA) (2009); Newcastle upon Tyne Hospitals NHS Foundation Trust (2024); University of Illinois Chicago (2019–2026); University of Chicago (2013–2026); University of Chicago Medical Center (2013–2025); Office of the Director (2001); St Vincent’s Private Hospital Sydney (2021); Northwestern University (2023); Twin Cities Orthopedics (2002); Palmetto Hematology Oncology (2019–2020); Peking University People's Hospital (2013); Cancer Research Center (2015); UPMC Hillman Cancer Center (2005); National Cancer Institute (2013); National Cancer Institute (2000–2012); Cellular Therapeutics (United Kingdom) (2026); Center for Cancer Research (2004–2012); University College London (2024); University of Nebraska Medical Center (1994–2000); University of Pennsylvania (2002–2005)

Faculty Researcher

38 h-index 288 pubs 6,953 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Michael R. Bishop's research focuses on the investigation and treatment of hematological malignancies, particularly acute lymphoblastic leukemia and aggressive B-cell lymphomas. He has been involved in multiple clinical trials evaluating novel immunotherapies, including CAR T-cell therapies. His publications include results from the ZUMA-3 study, which evaluated KTE-X19 (axicabtagene ciloleucel) in adult relapsed or refractory B-cell acute lymphoblastic leukemia, and a study on the second-line treatment of aggressive B-cell lymphoma using tisagenlecleucel or standard care. Bishop has also contributed to research on the patterns of use and outcomes of commercial CAR T-cell therapies for relapsed/refractory aggressive B-cell lymphomas and a phase 1 study of CART-ddBCMA for relapsed and refractory multiple myeloma.

His work also extends to quality of life metrics in pediatric cancer patients, as evidenced by his co-authorship on a joint international consensus statement for measuring quality of survival for patients with childhood cancer. Bishop maintains an active research lab and has a publication record of 275 papers with 6,833 citations, achieving an h-index of 38. He is designated as a highly cited researcher. His collaborations at the University of Arkansas for Medical Sciences include Muthu Veeraputhiran, Akash Mukherjee, Thomas J. Kelly, and Brendan Crawford.